Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research

Montclair State Designated ‘Public Research’ University; Readies Launch of $22 Million Computer Science Facility

Montclair, NJ, September 5, 2017 — Vince Calico reports in NJBIZ that Montclair State University, after being designated a Public Research University by Gov. Chris Christie in July, is preparing to launch a 40,000-square-foot computer science facility in the fall of 2018, and is setting its sights on other major expansion projects.

The school is on a roll in terms of academic prestige: Christie signed legislation July 21 giving Montclair State the Public Research University designation just one month after the college was ranked among the best schools for the money by Money Magazine.

In addition to the prestige, the new designation allows Montclair State to once again enter into public-private partnerships to construct new facilities and make financial aid available to hundreds of more students. Continue reading

NFL to Make $40 Million Available for Medical Research; A Board Will Evaluate Proposals

New York, NY, August 31, 2017 — Barry Wilner of the Associated Press reports that, a year after the NFL pledged $100 million in support of independent medical research and engineering advancements, a huge chunk of that soon will be awarded to such research, primarily dedicated to neuroscience.

A Scientific Advisory Board assembled by the NFL is set to launch its program to solicit and evaluate research proposals for funding.

The board, comprised of independent experts, doctors, scientists and clinicians, and chaired by retired U.S. Army General Peter Chiarelli, will provide direction for the $40 million allocated under the league’s initiative. Continue reading

Rutgers Cancer Institute Research Dr. Jennifer Tsui Receives $729K American Cancer Society Grant

Dr. Jennifer Tsui

New Brunswick, NJ, August 30, 2017 — Jennifer Tsui, PhD, a researcher at Rutgers Cancer Institute of New Jersey, has been awarded a $729,000 Mentored Research Scholar Grant in Applied and Clinical Research from the American Cancer Society to further explore health care delivery and care transitions for underserved cancer patients.

The award supports investigators who are in the early stages of their career in becoming independent researchers as either clinician scientists or cancer control and prevention investigators.

Despite evidence that vulnerable populations often receive poor quality care, few studies have focused on understanding the underlying health care processes that contribute to suboptimal cancer care or poor transitions between primary care and oncology care. Continue reading

Hackensack Meridian and NJ Innovation Institute Cut Ribbon on Agile Strategies Lab, First Health Care Incubator in State

Newark, NJ, August 28, 2017 — Anjalee Khemlani reports on NJBIZ that Agile Strategies Lab — a partnership between Hackensack Meridian Health and New Jersey Innovation Institute (NJII) — held a ribbon-cutting August 15, officially opening the first incubator for health care in New Jersey.

The incubator, which Khemlani first reported on March 9, is located in Newark.  It is being funded by $25 million from the health system and is designed as a space where a “Shark Tank”-like expert panel will hear pitches that aim to solve health care issues. Continue reading

NJEDA to Make Additional Lab Space Available for State’s Growing Biotechnology Companies

Trenton, NJ, August 18, 2017 — The New Jersey Economic Development Authority (EDA) yesterday announced it will again expand its successful incubator program with the creation of the Biotechnology Development Center (BDC) on the 50-acre Technology Centre of New Jersey research park in North Brunswick.

The BDC will offer suites of intermediate lab and office space from 3,400 to 10,000 square feet for emerging life sciences companies including those that have outgrown incubator space and other early stage companies looking to expand. More than 32,600 square feet of new space is now available at the BDC. Continue reading

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

Dr. Janice M. Mehnert

New Brunswick, NJ, August 18, 2017 — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.

That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).

Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses bak to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.” Continue reading

Opinion: Assemblymen and Stevens President Urge ‘Restore Funding to Turbocharge NJ’s Research and Development’

Trenton, NJ, August 16, 2017Assemblyman Raj Mukherji (D-Hudson), Assemblyman Troy Singleton (D-Burlington) and Dr. Nariman Farvardin, president of Stevens Institute of Technology, write on innovation and Assembly No. 5123 in an op-ed published on August 15 in The Star-Ledger:

One need only to look at the top performers in the S&P 500 — Amazon, Apple, Google parent Alphabet and Facebook — to confirm an indisputable fact about our modern economy: Technological innovation is the key driver of economic growth.

Policymakers who ignore technology’s disruptive impact on markets, industries and jobs do so at their constituents’ peril. (Think Amazon’s impact on the retail industry.) Continue reading

Rutgers New Jersey Medical School Scientists Study How Worm Infections Can Weaken Immune Systems — And Life-Saving Vaccinations

New Brunswick, NJ, August 9, 2017 — Why are malaria, tuberculosis and hepatitis so prevalent in developing nations?  And why are most vaccines against these pathogens so ineffective?

Two Rutgers New Jersey Medical School scientists believe they may have found an answer in parasitic intestinal worms — which infect more than 1.5 billion people worldwide and can weaken the immune system’s ability to fend off disease, rendering vaccines less effective.

George Yap and William Gause received a $3 million grant from the National Institutes of Health this spring to study how worms prevent vaccinations from bolstering the immune system. Continue reading

U.S. Senate Passes Bill to Improve Cancer Drugs for Children

Washington, DC, August 7, 2017 — Ledyard King reports in USA Today that, until now, drug companies have been free to decide whether to pursue treatments for pediatric cancers as part of their work on adult cancers.

They won’t have much choice going forward.

The Senate on August 3 overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for childhood cancers. Continue reading

California Received Largest NIH Awards Between 2007-2016; New Jersey Award Funding Decreased

Bethesda, MD, August 5, 2017 — The State Science & Technology Institute (SSTI) news blog reports that, with a focus on improving health, driving economic growth, and expanding the country’s research capacity, the National Institutes of Health (NIH) is the largest public funder of biomedical research in the world.

Because of NIH’s central role in supporting science, technology, and innovation, a better understanding of the agency’s footprint may be helpful to the technology-based economic development practitioner community.

This edition of Useful Stats utilizes data from NIH’s Research Portfolio Online Reporting Tool (RePORT) and covers each year from 2007 to 2016. The data does not include projects funded by the American Recovery and Reinvestment Act of 2009. Continue reading